ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease

ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.

Go to News Site